KIRKLAND, Wash.--(BUSINESS WIRE)-- Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced a banner 12 months for the company marked by expansion of the JETSTREAM family of products to include several new devices, including the JETSTREAM G3® catheter for treatment above the knee, the JETSTREAM G3 SF catheter for treatment below the knee and the JETWIRE™ guide wire. The company also saw a 21 percent increase in revenue in Q1 2011 over Q1 2010. Pathway’s products have been used to treat more than 15,000 patients suffering from PVD worldwide.
“Our focus at Pathway is to continually expand the JETSTREAM family of products to meet the needs of a growing PVD patient population and to ensure that physicians have the most comprehensive tools on the market for the safe and effective treatment of all forms of the disease. It is great to see that our efforts have resulted in a record year of growth for our company,” said Pathway Medical Technologies President and CEO Paul Buckman. “As we close the first quarter of 2011, we are committed to building upon this legacy of product innovation and customer momentum and continuing to grow our share of the atherectomy market as we strive to become the undisputed leader in endovascular treatments for PVD.”
Pathway’s flagship product, JETSTREAM, is a peripheral revascularization catheter designed to remove all forms of artery-clogging plaque in the lower limbs of patients. This innovative and minimally invasive solution clears blockages in the peripheral vasculature, restores blood flow and effectively treats PVD.
Building on the success of its first two generations of devices, Pathway introduced the 3rd generation JETSTREAM G3 to the U.S. market in January 2010 following 510(k) clearance from the U.S. Food & Drug Administration (FDA). With a new distal cutter and enhanced aspiration efficiency, JETSTREAM G3 offered significant improvement in cutting and disease removal, enabling physicians to treat PVD more quickly, safely and effectively than any existing technologies.
In mid-2010, the company followed up with 510(k) clearance for JETSTREAM G3 SF (Small Fixed), a catheter optimized for treating blockages below the knee (BTK). JETSTREAM G3 SF features a smaller, fixed cutter designed for enhanced performance in tortuousity (curves) and better navigation of the device through smaller arteries of the lower leg, allowing physicians to treat a broader range of PVD patients, including a greater number of patients with critical limb ischemia and diabetes in the BTK population. JETSTREAM G3 SF is the only below the knee device on the market that offers active aspiration, a feature that continually removes debris from the treatment site while the device is operating.
In addition, Pathway has launched JETWIRE, a frontline guide wire designed for use in angiographic procedures. JETWIRE is used to help introduce and position catheters and other interventional devices within the coronary and peripheral vasculature. Designed for use with the JETSTREAM family of products, JETWIRE features proprietary polytetrafluoroethylene (PTFE) coating that delivers uniform consistency, enhanced lubricity and excellent durability. Additional features include: a 2 cm radiopaque tip that enhances visualization under fluoroscopy for precise guide wire placement; a distal tip that can be shaped to aid in sub-selective navigation within the vasculature; and 1:1 torque response that facilitates navigation of tortuous anatomy with precise control.
JETSTREAM G3 and JETSTREAM G3 SF have also received CE Mark approval.
About JETSTREAM
JETSTREAM is a peripheral revascularization catheter designed to remove all kinds of artery-clogging plaque in the lower limbs of patients. This innovative and minimally invasive solution clears blockages in the peripheral vasculature, restores blood flow and effectively treats PVD. JETSTREAM consists of a sterile, single-use catheter and control pod and a reusable, compact console that mounts to a standard I.V. stand. The catheter has a cutting tip that safely debulks and preemptively removes both hard and soft plaque, as well as calcium, thrombus and fibrotic lesions. Excised tissue and thrombus are continually aspirated from the peripheral treatment site through a port in the catheter to a collection bag located on the console. The distal portion of the catheter also possesses infusion ports that provide continuous infusion of sterile saline during the atherectomy procedure. Active aspiration is a safety feature that minimizes the risk of distal embolization.
With simple set up and an ergonomic design for easy operation by trained clinicians, JETSTREAM maximizes treatment effectiveness and offers renewed hope for non-surgical candidates and the benefits of a minimally invasive treatment option, including faster recovery and decreased systemic complications.
About Pathway Medical Technologies, Inc.
Pathway Medical Technologies, Inc. was founded to design, market and manufacture medical devices for the treatment of vascular disease. The company’s initial focus is treating peripheral arterial disease (PAD) more quickly and effectively than existing technologies. An estimated 12 million people are afflicted by PAD in the U.S. and that number is projected to grow to over 20 million during the next 10 years. The company’s Jetstream® device allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing both hard and soft diseased tissue. For further information, visit the company’s Web site at www.pathwaymedical.com.
Contact:
Schwartz Communications for Pathway Medical Technologies Marisa Borgasano, 781-684-0770 PathwayMedical@schwartz-pr.com
